190 related articles for article (PubMed ID: 21057002)
21. The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells.
Wilhelmsen K; Khakpour S; Tran A; Sheehan K; Schumacher M; Xu F; Hellman J
J Biol Chem; 2014 May; 289(19):13079-100. PubMed ID: 24644287
[TBL] [Abstract][Full Text] [Related]
22. The Cannabinoid WIN 55,212-2 Reduces Delayed Neurologic Sequelae After Carbon Monoxide Poisoning by Promoting Microglial M2 Polarization Through ST2 Signaling.
Du JJ; Liu ZQ; Yan Y; Xiong J; Jia XT; Di ZL; Ren JJ
J Mol Neurosci; 2020 Mar; 70(3):422-432. PubMed ID: 31732924
[TBL] [Abstract][Full Text] [Related]
23. Cannabinoid WIN 55,212-2 induces cell cycle arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in prostate cancer in a cannabinoid-receptor 2 dependent manner.
Roberto D; Klotz LH; Venkateswaran V
Prostate; 2019 Feb; 79(2):151-159. PubMed ID: 30242861
[TBL] [Abstract][Full Text] [Related]
24. Reactive oxygen species controls endometriosis progression.
Ngô C; Chéreau C; Nicco C; Weill B; Chapron C; Batteux F
Am J Pathol; 2009 Jul; 175(1):225-34. PubMed ID: 19498006
[TBL] [Abstract][Full Text] [Related]
25. Cannabinoid receptor-independent actions of the aminoalkylindole WIN 55,212-2 on trigeminal sensory neurons.
Price TJ; Patwardhan A; Akopian AN; Hargreaves KM; Flores CM
Br J Pharmacol; 2004 May; 142(2):257-66. PubMed ID: 15155534
[TBL] [Abstract][Full Text] [Related]
26. Combined antiproliferative effects of the aminoalkylindole WIN55,212-2 and radiation in breast cancer cells.
Emery SM; Alotaibi MR; Tao Q; Selley DE; Lichtman AH; Gewirtz DA
J Pharmacol Exp Ther; 2014 Feb; 348(2):293-302. PubMed ID: 24259678
[TBL] [Abstract][Full Text] [Related]
27. Topical cannabinoid antinociception: synergy with spinal sites.
Dogrul A; Gul H; Akar A; Yildiz O; Bilgin F; Guzeldemir E
Pain; 2003 Sep; 105(1-2):11-6. PubMed ID: 14499415
[TBL] [Abstract][Full Text] [Related]
28. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide.
Facchinetti F; Del Giudice E; Furegato S; Passarotto M; Leon A
Glia; 2003 Jan; 41(2):161-8. PubMed ID: 12509806
[TBL] [Abstract][Full Text] [Related]
29. Exposure to cannabinoid agonist WIN 55,212-2 during early adolescence increases alcohol preference and anxiety in CD1 mice.
Frontera JL; Gonzalez Pini VM; Messore FL; Brusco A
Neuropharmacology; 2018 Jul; 137():268-274. PubMed ID: 29778010
[TBL] [Abstract][Full Text] [Related]
30. Cannabinoids Induce Cell Death and Promote P2X7 Receptor Signaling in Retinal Glial Progenitors in Culture.
Freitas HR; Isaac AR; Silva TM; Diniz GOF; Dos Santos Dabdab Y; Bockmann EC; Guimarães MZP; da Costa Calaza K; de Mello FG; Ventura ALM; de Melo Reis RA; França GR
Mol Neurobiol; 2019 Sep; 56(9):6472-6486. PubMed ID: 30838518
[TBL] [Abstract][Full Text] [Related]
31. Arthritis and cannabinoids: HU-210 and Win-55,212-2 prevent IL-1alpha-induced matrix degradation in bovine articular chondrocytes in-vitro.
Mbvundula EC; Bunning RA; Rainsford KD
J Pharm Pharmacol; 2006 Mar; 58(3):351-8. PubMed ID: 16536902
[TBL] [Abstract][Full Text] [Related]
32. Cannabinoids attenuate cancer pain and proliferation in a mouse model.
Saghafi N; Lam DK; Schmidt BL
Neurosci Lett; 2011 Jan; 488(3):247-51. PubMed ID: 21094209
[TBL] [Abstract][Full Text] [Related]
33. Suppression of outward K⁺ currents by WIN55212-2 in rat retinal ganglion cells is independent of CB1/CB2 receptors.
Zhang CQ; Wu HJ; Wang SY; Yin S; Lu XJ; Miao Y; Wang XH; Yang XL; Wang Z
Neuroscience; 2013 Dec; 253():183-93. PubMed ID: 24013008
[TBL] [Abstract][Full Text] [Related]
34. Effects of the cannabinoid receptor agonist WIN 55,212-2 on operant behavior and locomotor activity in rats.
Drews E; Schneider M; Koch M
Pharmacol Biochem Behav; 2005 Jan; 80(1):145-50. PubMed ID: 15652390
[TBL] [Abstract][Full Text] [Related]
35. The antimitogenic effect of the cannabinoid receptor agonist WIN55212-2 on human melanoma cells is mediated by the membrane lipid raft.
Scuderi MR; Cantarella G; Scollo M; Lempereur L; Palumbo M; Saccani-Jotti G; Bernardini R
Cancer Lett; 2011 Nov; 310(2):240-9. PubMed ID: 21807457
[TBL] [Abstract][Full Text] [Related]
36. Modulation of paraoxon toxicity by the cannabinoid receptor agonist WIN 55,212-2.
Nallapaneni A; Liu J; Karanth S; Pope C
Toxicology; 2006 Oct; 227(1-2):173-83. PubMed ID: 16956707
[TBL] [Abstract][Full Text] [Related]
37. The cannabinoid receptor agonists, anandamide and WIN 55,212-2, do not directly affect mu opioid receptors expressed in Xenopus oocytes.
Kracke GR; Stoneking SP; Ball JM; Tilghman BM; Washington CC; Hotaling KA; Johnson JO; Tobias JD
Naunyn Schmiedebergs Arch Pharmacol; 2007 Dec; 376(4):285-93. PubMed ID: 17960365
[TBL] [Abstract][Full Text] [Related]
38. The cannabinoid agonist WIN 55,212-2 inhibits TNF-alpha-induced neutrophil transmigration across ECV304 cells.
Nilsson O; Fowler CJ; Jacobsson SO
Eur J Pharmacol; 2006 Oct; 547(1-3):165-73. PubMed ID: 16928371
[TBL] [Abstract][Full Text] [Related]
39. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer.
Qamri Z; Preet A; Nasser MW; Bass CE; Leone G; Barsky SH; Ganju RK
Mol Cancer Ther; 2009 Nov; 8(11):3117-29. PubMed ID: 19887554
[TBL] [Abstract][Full Text] [Related]
40. Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission.
Haller J; Mátyás F; Soproni K; Varga B; Barsy B; Németh B; Mikics E; Freund TF; Hájos N
Eur J Neurosci; 2007 Apr; 25(8):2445-56. PubMed ID: 17445240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
